Effect of renvastinib on the level of AFP-L3, AFP, DCP and immune function in patients with hepatocellular carcinoma after radiofrequency ablation

DONG Dandan , QIU Li , HU Yi , LIU Jianzhong

PDF(6984 KB)
主办：上海医药工业研究院
　　　中国药学会
ISSN 1672-9188   CN 31-1939/R   SLYHAA
World Clinical Drug
PDF(6984 KB)
World Clinical Drug ›› 2025, Vol. 46 ›› Issue (3) : 254-259. DOI: 10.13683/j.wph.2025.03.008
Article

Effect of renvastinib on the level of AFP-L3, AFP, DCP and immune function in patients with hepatocellular carcinoma after radiofrequency ablation

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 46(3): 254-259 https://doi.org/10.13683/j.wph.2025.03.008

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(6984 KB)

Accesses

Citation

Detail
Sections
Recommended

/

〈 〉